TCRR
Closed
Tcr2 Therapeutics Inc
1.48
-0.09 (-5.73%)
Last Update: 01 Jun 2023 16:30:00
Yesterday: 1.57
Day's Range: 1.48 - 1.48
Send
sign up or login to leave a comment!
When Written:
1.545
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company that focuses on the development of novel T cell therapies for cancer patients. The company's proprietary TRuC™ (TCR Fusion Construct) platform enables the engineering of T cells with enhanced specificity and potency against a range of solid tumors. TCR2's lead product candidate, TC-210, is a first-in-class TRuC-T cell therapy that is being evaluated in Phase 1/2 clinical trials for the treatment of patients with mesothelin-expressing solid tumors. The company is headquartered in Cambridge, Massachusetts and was founded in 2015.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








